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ABSTRACT
Objective: The SAVOR TIMI–53 study reported a
significant increase in the risk of hospitalisation for heart
failure (HF) in patients treated with a DPP-4 inhibitor
(DPP-4i) in comparison with placebo. A recent case-
control study in part confirmed this risk signal. Our aim
was to compare the occurrence of HF in relation to DPP-
4i use versus any antidiabetic treatment.
Design: Population-based matched case-control study
conducted using administrative data.
Setting: The Italian Region of Piedmont (4.4 million
inhabitants).
Participants: From a database of 282 000 patients
treated with antidiabetic drugs, we identified 14 613
hospitalisations for HF, 7212 incident cases, and 1727
hospital re-admissions between 2008 and 2012; each
case was matched for gender, age and antidiabetic
therapy with 10 controls; cases and controls were
compared for exposure to DPP-4i.
Outcome measures: ORs and 95% CIs were
calculated by fitting a conditional logistic model. All
analyses were adjusted for available risk factors for HF.
Results:We found no increased risk of hospitalisation
for HF associated with the use of DPP-4i (OR for
admission for HF 1.00 (0.94 to 1.07), incident HF1.01
(0.92 to 1.11), recurrent HF 1.02 (0.84 to 1.22)). All-
cause mortality was 6% lower in DPP-4i users
(p<0.001), whereas insulin users showed an excess of
risk for any type of hospital admission (19%) and death
(20%) (p<0.001).
Conclusions: Our findings suggest that, in an
unselected population of diabetic patients, the use of
DPP-4i is not associated with an increased risk of HF.
The favourable impact on all-cause mortality should be
viewed with caution and also other explanations
investigated.
INTRODUCTION
DPP-4 inhibitors (DPP-4i), or gliptins, are
oral agents that delay the catabolism of
native GLP-1 by inhibiting the endogenous
enzyme dipeptidyl peptidase 4 (DPP-4), thus
extending the life of native GLP-1. They have
attracted growing interest as first line therap-
ies for type 2 diabetes largely because they
are effective in controlling HbA1c while
reducing the risk of hypoglycaemia and
weight gain. Data from trials with glycaemic
endpoints suggest that they also exert a pro-
tective effect on cardiovascular risk.1 In the
first published trial with cardiovascular end-
points,2 saxagliptins neither increase, nor
reduce, the risk of a composite of nonfatal
myocardial infarction (MI) with nonfatal
stroke or cardiovascular death, thereby
Strengths and limitations of this study
▪ This study suggests that, in an unselected popu-
lation of diabetic patients, the use of DPP-4i is
not associated with an increased risk of HF.
▪ The study population was representative of the
real type 2 diabetes population seen in Europe,
without any selection based on insurance claims
or age cut-off, which distinguishes it from other
published studies.
▪ Hospitalisation for HF was evaluated as admis-
sion, incidence or recurrence, and all five drugs
currently available on the market were included.
▪ The main limitation is that weak associations
between DPP-4i use and heart failure cannot be
ruled out; but if they do exist, they are not so
large but if they were to exist, they would be
relatively small.
▪ While looking forward to the results of ongoing
trials, practitioners can be reassured that the
unexpected association reported in the SAVOR
TIMI study has not been confirmed in the real
world.
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meeting the primary safety objective. However, as com-
pared with placebo, saxagliptin was unexpectedly asso-
ciated with a 27% excess risk of hospitalisation for heart
failure (HF) (overall HR 1.27 (95% CI 1.07 to 1.51)).
Detailed sub-analyses3 4 revealed that the absolute differ-
ence between groups was mainly seen during the first
6 months of therapy and that there was no increased risk
of death due to heart failure. No clinically relevant
factors predictive of increased relative risk with saxaglip-
tin treatment could be definitively identified.5 A subse-
quent meta-analysis of all registrative trials with DPP-4i
showed an association between the use of this class of
drugs and increased risk of HF, which disappears when
excluding cardiovascular outcome trials.6
Conflicting evidence for an association between sita-
gliptin use and hospitalisation for heart failure in some
specific conditions comes from recent observational
studies. Wang et al7 found an increased risk of hospitalisa-
tion for HF in with sitagliptin use in Taiwanese insured
individuals whereas Chen et al8 reported no increased
risk in patients with history of chronic kidney disease and
myocardial infarction. Weir et al9 in particular reported
that in a case-control study, based on an administrative
database of US middle-aged adults with type 2 diabetes,
treatment with sitagliptin was associated with an
increased probability of hospitalisation for heart failure
only among patients with pre-existing heart failure.
This safety issue is relevant for diabetes care because
the rates of heart failure and hospitalisation are higher
in patients with type 2 diabetes than in the non-diabetic
population, regardless of treatment.10–12 Further compli-
cating the question is that several drugs commonly used
in the treatment of type 2 diabetes have been suspected
to increase the risk of HF.13
In light of the concerns over a possible HF risk asso-
ciated with DPP-4i, we thought it useful to perform a
matched case-control study to explore whether the same
increased risk as seen in the SAVOR-TIMI study could be
detectable in the real world and in an unselected popu-
lation. To the best of our knowledge, no such analysis
has been performed on data from European administra-
tive databases which, by virtue of the universalistic care
of European national health systems, encompass the
whole population and include all types of available
DPP-4i.
METHODS
Study design and participants
We conducted a population-based nested case-control
study using regional administrative data from Piedmont
(population about 4.4 million) Italy. The population is
covered by an automated system of databases containing
the records of all drugs dispensed from all regional
pharmacies and hospital discharges reimbursed by the
Italian National Health System. These archives can be
linked together by a unique anonymous identifier that is
encrypted to protect the patient’s privacy. Because this
automated system is anonymous, ethical committee
approval and informed consent for this study were not
required.
Procedures
We extracted information from the regional drug pre-
scription database for individuals aged 56 years or older
who were dispensed at least one dose of any drug to treat
diabetes between 1 January 2009 and 31 December 2013
(DPP-4i were not available in Italy before 2008). Only
Piedmont residents were included. To minimise the
chance of inclusion of patients with type 1 diabetes, we
linked the database to the regional hospital discharge
database, which contains the records of all hospital
admissions between 1995 and 2013. Excluded were indivi-
duals with an International Classification of Diseases, 9th
Edition, Clinical Modification (ICD-9-CM) code for type
1 diabetes mellitus (250.x1 or 250.x3). Furthermore, as
glitazones (TZD) increase the risk of heart failure, all
patients who had received a prescription for TZD during
the study period were excluded.
Selection of cases
We used four different definitions for cases. First, we iden-
tified all patients who had at least one discharge for heart
failure, defined as ICD-9-CM codes 402.01, 402.11, 402.91,
425.4, 425.5, 425.9, 428 or 518.4 as the primary discharge
diagnosis at any time after the first exposure to antidia-
betic drugs (ie, date of dispensation). For patients with
more than one discharge for heart failure, we only
included the first episode (ie, the hospital admission
closest to 1 January 2009). Second, we identified ‘incident’
cases of heart failure, defined as patients discharged with a
diagnosis of heart failure (defined as above) during the
study period, without a previous hospitalisation for heart
failure in the discharge diagnosis (either main or second-
ary) during the previous 60 months. Third, similarly to the
study by Weir et al,9 we followed up incident cases (defined
as above) to identify ‘first re-hospitalisations’ of those
patients who had been admitted to hospital for a diagnosis
of heart failure. Finally, we considered as cases all deaths
(of any cause) that occurred in the population during the
study period. Also included were Piedmont residents dis-
charged from any hospital located outside Piedmont,
because information on exposure to dispensed drugs is
available for all patients residing in the region. Similarly,
we included the deaths of Piedmont residents wherever
they occurred in Italy.
Selection of controls
To identify controls, we randomly selected 10 controls
from the same population source for each case,
matched for year of birth (within a 5-year age band), sex
and year of first exposure to antidiabetic drugs. Controls
were selected one subject at a time with replacement.
The process was repeated for each outcome. Matching
was carried out by the study statistician (RP) with the
use of an automated computer program.
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Exposure to DPP-4 inhibitors
We used the regional drug database to identify cases
and controls who had been prescribed DPP-4i at any time
in the 6 months before the hospital admission date. We
used the hospital admission date of cases to calculate the
exposure windows for controls. DPP-4i were selected
according to the Anatomical Therapeutic Chemical (ATC)
Classification System; ATC codes A10BH01+A10BD07
(Sitagliptin), A10BH02+A10BD08 (Vildagliptin), A10BH03
+A10BD10 (Saxagliptin) and A10BH05+A10BD11
(Linagliptin) were considered.
Ascertainment of potential confounders
We defined potential confounders from the regional
hospital discharge database as hospital admissions that
occurred up to 5 years before the index date for ischae-
mic heart diseases (ICD-9-CM 410–414). Likewise, we
also included individuals who had been treated with gli-
mepiride (ATC code A10BB12) or glibenclamide (ATC
code A10BB01) in the 6 months prior to the date of hos-
pital admission. Treatment with insulin (ATC A10A) in
the 6 months prior to the date of hospital admission was
regarded as proxy of severity of disease.
Statistical analysis
We calculated the proportions of categorical variables in
cases and controls, and assessed the differences in base-
line characteristics with the χ2 test. We estimated the risk
of the four different outcomes associated with dispensa-
tion of any DPP-4i by fitting conditional logistic regres-
sion models, expressed as ORs, and corresponding 95%
CIs. We adjusted the statistical models for the aforemen-
tioned confounders. Confounders included in the final
models were past history of ischaemic heart disease,
insulin use and glimepiride or glibenclamide (consid-
ered together) use. In the sensitivity analyses, we
assessed the use of DPP-4i at any time before hospital
admission or death. All analyses were performed using
the SAS PHREG procedure V.9.2.
RESULTS
During the study period, 14 613 cases of hospital admis-
sion for heart failure, 7212 incident cases of heart
failure, 1727 cases of re-admission and 38 248 deaths
occurred within this population of patients with type 2
diabetes. Compared with controls, the use, as well as the
type, of DPP-4i did not differ between cases and controls
for heart failure outcomes (between 1.8 and 2.0% of
both cases and controls were on gliptins), whereas the
use of insulin, but not of glibenclamide, was more fre-
quent among the cases. There was a higher prevalence
of ischaemic heart disease among the cases. When mor-
tality was considered as an outcome, exposure to DPP-4i
was lower among the cases than the controls (0.8% vs
1.8%) (table 1).
After adjustment for available confounders, the use of
gliptins up to 6 months before any of the outcomes
considered was not associated with the risk of hospitalisa-
tion for heart failure (OR 1.00, 95% CI 0.94 to 1.07;
p=0.9832), incident heart failure (OR 1.01, 95% CI 0.92
to 1.11; p=0.7808), hospital re-admission for heart failure
(OR 1.02, 95% CI 0.84 to 1.22; p=0.8745), or death of any
cause (OR 0.94, 95% CI 0.90 to 0.98; p=0.0021). A history
of ischaemic heart disease or insulin use was associated
with an increased risk of all the outcomes considered,
except for hospital re-admission for heart failure
(table 2). In the sensitivity analysis, in which the time
window was extended to include DPP-4i use at any time
before the outcomes under study, the ORs were
unchanged for all outcomes: hospital admission (OR
0.99, 95% CI 0.94 to 1.05; p=0.8048), incident heart
failure (OR 1.01, 95% CI 0.93 to 1.09; p=0.8775), hospital
re-admission (OR 0.97, 95% CI 0.85 to 1.16; p=0.9558),
or death (OR 0.94, 95% CI 0.91 to 0.98; p=0.0018).
DISCUSSION
The question of whether or not therapy with DPP-4i may
increase the risk of heart failure has raised concern over
the safety of these drugs among practitioners.4 The key
message of our analysis is that, in a large unselected
population of treated individuals with type 2 diabetes,
no association was found, regardless of causality and as
borne out by the neutral OR independent of the sub-
group considered (Any admission, Incident or Re-admis-
sion for heart failure).
Our findings are in line with a very recent paper by Yu
et al,14 who reported no association between the use of
these incretin-based therapies, studied as a whole DPPi
and GLP1 receptor agonists, and incident heart failure
in patients with type 2 diabetes. The same concordance
exists with the general message from animal studies and
pathophysiological investigations, which found no detri-
mental effect of DPP-4i on cardiac function.15 16
However, it is a puzzling link because two other recent
physiopathological studies in patients produced unantici-
pated findings that treatment with DPP-4i could exacer-
bate heart failure.17 18 Moreover, since no plausible
explanation for the SAVOR TIMI 53 finding has been
forthcoming, it is difficult to speculate on the reasons
for the differences between their findings and our find-
ings in the drug-associated risk of heart failure.
Weir et al9 found a significantly increased risk of hospi-
talisation for heart failure associated with the use of sita-
gliptin among adults with type 2 diabetes, but only in
patients with pre existing heart failure, with a relevant
84% excess of risk. One possible, though still speculative,
explanation for this discrepancy could be an indication
bias contending that, before the SAVOR TIMI results
were published, DPP-4i use was well regarded and con-
sidered particularly safe in patients with left ventricular
dysfunction or renal insufficiency. On closer analysis, the
two study populations differ in average age (78 vs
54 years) and background antidiabetes therapies. An
additional difference lies in the choice of cases, with the
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Table 1 Baseline characteristics
Any admission for HF Incident HF Re-admission for HF All-cause mortality
Cases
(n=14 613)
Controls
(n=146 130) p Value
Cases
(n=7212)
Controls
(n=72 120) p Value
Cases
(n=1727)
Controls
(n=17 222) p Value
Cases
(n=38 248)
Controls
(n=382 313) p Value
Age at recruitment, years 78.0 (8.3) 77.9 (8.4) 78.3 (8.4) 78.2 (8.4) 77.9 (8.4) 77.9 (8.5) 80.2 (9.1) 79.9 (9.0)
Sex male 7690 (52.6) 76 900 (52.6) 3577 (49.6) 35 770 (49.6) 914 (52.9) 9102 (52.9) 19 215 (50.2) 191 983 (50.2)
DPP-4i use (6 months) 256 (1.8) 2881 (2.0) 0.0672 135 (1.9) 1285 (1.8) 0.5820 37 (2.1) 338 (2.0) 0.6090 306 (0.8) 6717 (1.8) <0.0001
DPP-4i use (any) 328 (2.2) 3636 (2.5) 0.0702 171 (2.4) 1657 (2.3) 0.6917 47 (2.7) 470 (2.7) 0.9853 477 (1.3) 8491 (2.2) <0.0001
Previous disorders or treatments
Ischaemic heart disease
(in the past 5 years)
3371 (23.1) 10 237 (7.0) <0.0001 879 (12.2) 5492 (7.6) <0.0001 281 (16.3) 2361 (13.7) 0.0034 4270 (11.2) 23 938 (6.3) <0.0001
Glimepiride or
glibenclamide (in the past
6 months)
1531 (10.5) 16 756 (11.5) 0.0003 916 (12.7) 8144 (11.3) 0.0003 172 (10.0) 1691 (9.8) 0.8516 3428 (9.0) 46 327 (12.1) <0.0001
Insulin (in the past
6 months)
5363 (36.7) 24 108 (16.5) <0.0001 2177 (30.2) 12 042 (16.7) <0.0001 730 (42.3) 4459 (25.9) <0.0001 14 159 (37.0) 64 477 (16.9) <0.0001
Data are mean (SD) or no. (%).
HF, heart failure.
Table 2 Matched ORs of different outcomes associated with exposure to DPP-4i in the 6 months before index date
Any admission for HF Incident HF Re-admission for HF All-cause mortality
Unadjusted OR
(95% CI); p value
Adjusted OR
(95% CI); p value
Unadjusted OR
(95% CI); p value
Adjusted OR
(95% CI); p value
Unadjusted OR
(95% CI); p value
Adjusted OR
(95% CI); p value
Unadjusted OR
(95% CI); p value
Adjusted OR
(95% CI); p value
DPP-4i use 0.99 (0.92 to 1.05);
p=0.6383
1.00 (0.94 to 1.07);
p=0.9832
1.01 (0.92 to 1.11);
p=0.8867
1.01 (0.92 to 1.11);
p=0.7808
1.01 (0.84 to 1.22);
p=0.8944
1.02 (0.84 to 1.22);
p=0.8745
0.93 (0.89 to 0.97);
p=0.0005
0.94 (0.90 to 0.98);
p=0.0021
Previous disorders or treatments
Ischaemic heart disease (in the past 5 years) 1.36 (1.31 to 1.40);
p=<0.0001
1.34 (1.29 to 1.38);
p=<0.0001
1.09 (1.04 to 1.14);
p=0.0003
1.08 (1.03 to 1.13);
p=0.0014
1.03 (0.96 to 1.11);
p=0.4455
1.02 (0.95 to 1.10);
p=0.6067
1.11 (1.09 to 1.14);
p=<0.0001
1.09 (1.07 to 1.12);
p=<0.0001
Glimepiride or glibenclamide (in the past
6 months)
0.99 (0.96 to 1.02);
p=0.3555
1.01 (0.98 to 1.04);
p=0.4844
1.02 (0.98 to 1.06);
p=0.3520
1.03 (0.99 to 1.08);
p=0.0998
1.00 (0.92 to 1.09);
p=0.9614
1.02 (0.93 to 1.11);
p=0.6751
0.96 (0.95 to 0.98);
p=<0.0001
0.98 (0.97 to 1.00);
p=0.0540
Insulin (in the past 6 months) 1.21 (1.18 to 1.24);
p=<0.0001
1.19 (1.17 to 1.22);
p=<0.0001
1.13 (1.10 to 1.17);
p=<0.0001
1.13 (1.10 to 1.17);
p=<0.0001
1.12 (1.06 to 1.19);
p=0.0001
1.12 (1.06 to 1.19);
p=0.0002
1.20 (1.19 to 1.22);
p=<0.0001
1.20 (1.18 to 1.21);
p=<0.0001
HF, heart failure.
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American population appearing as a rather select popu-
lation of young insured individuals.
The favourable impact of DPP-4i use on all-cause mortal-
ity is welcome but still warrants caution. It could confirm
recent observational data that suggested a reduction of
mortality in the Danish diabetic population on incretins.19
It should also be remembered, however, that DPP-4i use
can represent a marker of better specialty care.20
Our analysis, by contrast, beyond the expected role of
previous ischaemic heart disease as a factor underlying
impaired myocardial performance, revealed an important
link between insulin use and risk of heart failure for first
as well as for recurrent hospitalisation. This finding is
neither new nor surprising. In the last several years,
numerous observational studies have found insulin to be a
marker of poor cardiovascular outcomes, including heart
failure,21 raising the question of the possible pathogenetic
role of hypoglycaemic events. Why the outcomes of insulin
use in observational studies clash with the findings from
randomised controlled trials such as the UKPDS22 and
ORIGIN,23 and seem to dismiss the role insulin can play in
preventing complications, is perplexing. For instance, the
DAI study, the largest cohort study on complications of dia-
betes in Italy, found a correlation between insulin therapy
and the occurrence of coronary disease and stroke.24
Similar conclusions were reported for heart failure.25
A simple explanation would be that there is a typical indi-
cation bias. A more complex rationalisation would point to
the problem of clinical inertia: insulin in the real world is
given late, after chronic exposure to high glucose levels,
thus marking subjects with poor irreversible legacy. In
other words, the outcome after insulin therapy in observa-
tional studies may reflect the fact that it is initiated too late
rather than its appropriate use.
Our study has several strengths. It was conducted using
data retrieved from a population-based database repre-
sentative of the real type 2 diabetes population seen in
Europe, without any selection based on insurance claims,
and, in particular, with no age cut-off, two factors that dis-
tinguish it from other published studies using administra-
tive data. Our approach thus eliminated recall bias and
minimised selection bias. All five drugs currently available
on the market were included. Furthermore, as DPP-4i are
dispensed and reimbursed only by prescription, we are
confident to have included all dispensations.
Our study also has potential limitations, however.
Though the sample size is rather large, this should not
be a concern: with the use of a one-sided test at the
α=5% level, the smallest risk, greater than one, that
could be detected with 80% power is OR=1.16 for hos-
pital admissions, 1.24 for incident heart failure and 1.49
for hospital re-admissions. We are aware that a weaker
association between DPP-4i use and heart failure cannot
be ruled out; but if it does exist, it would be relatively
small. Another weakness is the missing data on meta-
bolic control and other clinical variables such as NT-pro
BNP levels, hypertension, heart valve defects and renal
failure, all of which could have impacted on
hospitalisation rates for heart failure. Nonetheless, there
is no reason why this could have favoured the control
group and thus masked the association. As a proxy of
diabetes severity, we adjusted for cardiovascular disease
and level of therapy. We did not consider medication
dose or adherence to therapy and, given the low preva-
lence of exposed individuals, we were unable to factor in
the effect of the different compounds separately. In add-
ition, the use of a database of dispensed drugs rather
than usage data might have overestimated DPP-4i use;
however, it is unlikely that this would have affected cases
and controls differently. Finally, only severe cases of
heart failure hospitalisation were considered, leaving
open the question of whether or not milder episodes of
cardiac insufficiency, not resulting in hospital admission,
could have been increased in DPP-4i users.
Ongoing trials, including the Sitagliptin Cardiovascular
Outcome Study26 and the Functional Impact of GLP-1
for Heart Failure Treatment,27 may help to clarify the
conflicting findings. Meanwhile, practitioners can be
reassured that the unexpected association reported in
the SAVOR TIMI study has not been confirmed in the
real world.
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